87 First-in-Human Study of [111In] XYIMSR-01 SPECT/CT, a Novel Carbonic Anhydrase IX Small Molecule in Patients with Metastatic Clear Cell Renal Cell Carcinoma
Yasser Ged · 2026
Read 87 First-in-Human Study of [111In] XYIMSR-01 SPECT/CT, a Novel Carbonic Anhydrase IX Small Molecule in Patients with Metastatic Clear Cell Renal Cell Carcinoma by Yasser Ged (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13535428.txt.
Description
Yasser Ged leads a first-in-human imaging trial in spread kidney cancer in a 2026 study. Clear cell kidney tumors almost always overproduce a surface enzyme, CAIX, after losing a key tumor suppressor. A small molecule that homes to that enzyme could light the tumors up on scans and later carry therapy.
The tracer XYIMSR-01, tagged with radioactive indium-111, was designed to clear fast and give same-day pictures with high contrast. Animal studies showed strong, selective tumor uptake. The phase I trial at one center now tests safety and scanning feasibility in untreated patients with at least two sizable metastases.
Catalog record
| CREATOR | Yasser Ged |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |